Payment overview · 2025
General Payments
$1,219.70
27 reported records · 10 companies
Healthcare provider profile · identity verified
John Michael Ham-Ying, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DELTONA, FL · NPI 1780683870
Verified facts
What the public records show
CMS Open Payments records show John Michael Ham-Ying, M.D. received $1,219.70 in general payments during 2025 across 27 reported records.
Janssen Scientific Affairs, LLC accounted for 29.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $357.81 | 29.3% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $273.66 | 22.4% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $121.85 | 10.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $117.99 | 9.7% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $89.41 | 7.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $74.28 | 6.1% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $62.11 | 5.1% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $58.86 | 4.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.38 | 3.2% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $24.35 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,219.70 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Scientific Affairs, LLC | $357.81 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $273.66 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $121.85 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $117.99 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $89.41 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $62.11 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $58.86 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $52.16 | 2 | 2025 |
Source payment records
|
|||||
| INVEGA TRINZA Normalized: invega trinza |
Drug | Janssen Scientific Affairs, LLC | $44.16 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.38 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.74 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 183 | 71 |
| Lisinopril | Lisinopril | 175 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 135 | 60 |
| Metformin Hcl | Metformin Hcl | 93 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 37 |
| Gabapentin | Gabapentin | 86 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 82 | 32 |
| Omeprazole | Omeprazole | 81 | 25 |
| Ozempic | Semaglutide | 72 | 11 |
| Furosemide | Furosemide | 63 | 30 |
| Losartan Potassium | Losartan Potassium | 59 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 57 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 20 |
| Montelukast Sodium | Montelukast Sodium | 47 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 21 |
| Eliquis | Apixaban | 40 | 13 |
| Simvastatin | Simvastatin | 40 | 16 |
| Jardiance | Empagliflozin | 38 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 38 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 18 |
| Farxiga | Dapagliflozin Propanediol | 32 | 12 |
| Carvedilol | Carvedilol | 29 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 11 |
| Metformin Hcl Er | Metformin Hcl | 27 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | 13 |
| Prednisone | Prednisone | 20 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,219.70 · 27 records | Janssen Scientific Affairs, LLC | AREXVY, CAPLYTA, Cologuard Collection Kit, INVEGA SUSTENNA, INVEGA TRINZA, Omnipod, QULIPTA, QUTENZA, UBRELVY, VRAYLAR, XIFAXAN, ZEPBOUND | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error